Home/Filings/4/0001093557-25-000018
4//SEC Filing

Dolan Matthew Vincent 4

Accession 0001093557-25-000018

CIK 0001093557other

Filed

Jan 29, 7:00 PM ET

Accepted

Jan 30, 6:44 PM ET

Size

7.2 KB

Accession

0001093557-25-000018

Insider Transaction Report

Form 4
Period: 2025-01-28
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
  • Award

    Common Stock

    2025-01-28+3,04843,227 total
  • Sale

    Common Stock

    2025-01-29$86.91/sh1,183$102,82042,044 total
Footnotes (3)
  • [F1]Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
  • [F2]Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.
  • [F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Issuer

DEXCOM INC

CIK 0001093557

Entity typeother

Related Parties

1
  • filerCIK 0001914994

Filing Metadata

Form type
4
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 6:44 PM ET
Size
7.2 KB